ES2690943T3 - Anticuerpos monoclonales contra la progastrina y sus utilizaciones - Google Patents

Anticuerpos monoclonales contra la progastrina y sus utilizaciones Download PDF

Info

Publication number
ES2690943T3
ES2690943T3 ES10768878.0T ES10768878T ES2690943T3 ES 2690943 T3 ES2690943 T3 ES 2690943T3 ES 10768878 T ES10768878 T ES 10768878T ES 2690943 T3 ES2690943 T3 ES 2690943T3
Authority
ES
Spain
Prior art keywords
hpg
seq
antibody
mab
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10768878.0T
Other languages
English (en)
Spanish (es)
Inventor
Julie Pannequin
Laure Boudier
Dominique Joubert
Frédéric HOLLANDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Progastrine et Cancers SARL
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Progastrine et Cancers SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2690943(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Progastrine et Cancers SARL filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of ES2690943T3 publication Critical patent/ES2690943T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES10768878.0T 2009-10-16 2010-10-15 Anticuerpos monoclonales contra la progastrina y sus utilizaciones Active ES2690943T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
US252625P 2009-10-16
PCT/EP2010/006329 WO2011045080A2 (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses

Publications (1)

Publication Number Publication Date
ES2690943T3 true ES2690943T3 (es) 2018-11-23

Family

ID=43086711

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10768878.0T Active ES2690943T3 (es) 2009-10-16 2010-10-15 Anticuerpos monoclonales contra la progastrina y sus utilizaciones
ES18185172T Active ES2973217T3 (es) 2009-10-16 2010-10-15 Anticuerpos monoclonales contra la progastrina y sus utilizaciones

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18185172T Active ES2973217T3 (es) 2009-10-16 2010-10-15 Anticuerpos monoclonales contra la progastrina y sus utilizaciones

Country Status (42)

Country Link
US (7) US9611320B2 (enExample)
EP (2) EP2488551B1 (enExample)
JP (3) JP5985987B2 (enExample)
KR (2) KR101640520B1 (enExample)
CN (2) CN102791735B (enExample)
AP (1) AP2012006262A0 (enExample)
AR (1) AR078659A1 (enExample)
AU (1) AU2010306119A1 (enExample)
BR (1) BR112012008818B1 (enExample)
CA (1) CA2777691C (enExample)
CL (1) CL2012000914A1 (enExample)
CR (1) CR20120184A (enExample)
CU (1) CU24196B1 (enExample)
CY (1) CY1120913T1 (enExample)
DK (1) DK2488551T3 (enExample)
EA (2) EA201791876A1 (enExample)
EC (1) ECSP12011796A (enExample)
ES (2) ES2690943T3 (enExample)
GE (1) GEP201706604B (enExample)
GT (1) GT201200114A (enExample)
HN (1) HN2012000708A (enExample)
HR (1) HRP20181645T1 (enExample)
IL (2) IL219019B (enExample)
IN (1) IN2012DN03348A (enExample)
LT (1) LT2488551T (enExample)
MA (1) MA33747B1 (enExample)
MX (1) MX351635B (enExample)
NI (1) NI201200054A (enExample)
NZ (2) NZ701709A (enExample)
PE (1) PE20121649A1 (enExample)
PH (1) PH12012500711B1 (enExample)
PL (2) PL2488551T3 (enExample)
PT (1) PT2488551T (enExample)
RS (1) RS57966B1 (enExample)
SG (1) SG10201704933PA (enExample)
SI (1) SI2488551T1 (enExample)
SM (1) SMT201800628T1 (enExample)
TN (1) TN2012000159A1 (enExample)
TW (1) TWI537002B (enExample)
UA (1) UA106771C2 (enExample)
WO (1) WO2011045080A2 (enExample)
ZA (1) ZA201202642B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
PL2488551T3 (pl) * 2009-10-16 2019-01-31 Progastrine Et Cancers S.À R.L. Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
CA2793647C (en) * 2010-03-24 2020-09-01 Biorealites Prophylaxis of colorectal and gastrointestinal cancer
BR112013002012A2 (pt) * 2010-07-26 2019-08-27 Centre Nat Rech Scient métodos e composições para terapia de câncer de fígado
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
WO2012164035A1 (en) 2011-06-01 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
JP6450381B2 (ja) 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
EP3797793A1 (en) 2014-04-18 2021-03-31 The Research Foundation of the State University of New York at Buffalo Humanized anti-tf-antigen antibodies
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
AU2016324021A1 (en) * 2015-09-15 2018-04-12 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
MA43550A (fr) * 2015-12-31 2018-11-07 Syncerus S A R L Compositions et procédés d'évaluation du risque d'apparition d'un cancer
US11760808B2 (en) * 2015-12-31 2023-09-19 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
JP6909795B2 (ja) * 2015-12-31 2021-07-28 プロガストリン、エ、カンセル、エス、アー エル、エルＰｒｏｇａｓｔｒｉｎｅ Ｅｔ Ｃａｎｃｅｒｓ Ｓ．Ａ Ｒ．Ｌ． 胃癌の検出および治療のための組成物および方法
BR112019020224A2 (pt) * 2017-03-30 2020-05-12 Progastrine Et Cancers S.À R.L. Composições e métodos para o tratamento do câncer de pulmão
ES2904939T3 (es) * 2017-03-30 2022-04-06 Progastrine Et Cancers S A R L Composiciones y métodos para detectar y tratar el cáncer de próstata utilizando una molécula de unión a progastrina
PL3720879T3 (pl) * 2017-12-05 2022-09-12 Progastrine Et Cancers S.À R.L. Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu
WO2019110845A1 (en) 2017-12-08 2019-06-13 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
WO2019145537A1 (en) 2018-01-26 2019-08-01 Ecs-Progastrin Sa Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
KR102699073B1 (ko) * 2018-02-27 2024-08-26 이씨에스-프로가스트린 에스에이 면역치료요법용 생체표지자로서 프로가스트린
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
WO2021066751A1 (en) * 2019-10-02 2021-04-08 Aslan Pharmaceuticals Pte. Ltd. Antigen specific binding domains and antibody molecules
CN112062846A (zh) * 2020-04-27 2020-12-11 杭州博茵生物技术有限公司 一种g-17单克隆抗体及其应用
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN115724949A (zh) * 2022-12-12 2023-03-03 郑州伊美诺生物技术有限公司 一种鼠源lgG单克隆抗体及其制备方法、应用
CN116143920A (zh) * 2022-12-30 2023-05-23 南京岚煜生物科技有限公司 胃泌素17的单克隆抗体及其细胞株的制备方法和应用
US20250059271A1 (en) * 2023-08-16 2025-02-20 Barrelman Biosciences Llc Monoclonal antibodies against veterinary progastrin-like molecules and their uses
CN117567611B (zh) * 2023-11-22 2024-05-14 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US8158128B2 (en) * 2004-09-22 2012-04-17 Cancer Advances, Inc. Monoclonal antibodies to progastrin
PL2040753T3 (pl) * 2006-05-22 2019-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitory progastryny w leczeniu raka okrężnicy
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
PL2488551T3 (pl) * 2009-10-16 2019-01-31 Progastrine Et Cancers S.À R.L. Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania
CA2793647C (en) * 2010-03-24 2020-09-01 Biorealites Prophylaxis of colorectal and gastrointestinal cancer
BR112013002012A2 (pt) * 2010-07-26 2019-08-27 Centre Nat Rech Scient métodos e composições para terapia de câncer de fígado

Also Published As

Publication number Publication date
CU24196B1 (es) 2016-09-30
PH12012500711B1 (en) 2019-04-24
IL219019A0 (en) 2012-06-28
JP2017212992A (ja) 2017-12-07
AU2010306119A1 (en) 2012-05-03
EP2488551A2 (en) 2012-08-22
TN2012000159A1 (en) 2013-12-12
SI2488551T1 (sl) 2019-01-31
US10385126B2 (en) 2019-08-20
TW201119675A (en) 2011-06-16
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
MX2012004400A (es) 2012-06-27
JP2013507138A (ja) 2013-03-04
KR20150082672A (ko) 2015-07-15
CN104628857A (zh) 2015-05-20
PH12012500711A1 (en) 2012-11-12
CA2777691C (en) 2018-02-27
US20170174761A1 (en) 2017-06-22
KR20120091221A (ko) 2012-08-17
RS57966B1 (sr) 2019-01-31
US20170306012A1 (en) 2017-10-26
US20170306011A1 (en) 2017-10-26
NZ701709A (en) 2016-06-24
ECSP12011796A (es) 2012-06-29
ES2973217T3 (es) 2024-06-19
BR112012008818A2 (pt) 2018-05-22
ZA201202642B (en) 2013-06-26
US20180022802A1 (en) 2018-01-25
US9611320B2 (en) 2017-04-04
JP2015145380A (ja) 2015-08-13
CY1120913T1 (el) 2019-12-11
IL219019B (en) 2019-05-30
CN102791735A (zh) 2012-11-21
MX351635B (es) 2017-10-23
AP2012006262A0 (en) 2012-06-30
IN2012DN03348A (enExample) 2015-10-23
US11299542B2 (en) 2022-04-12
WO2011045080A2 (en) 2011-04-21
UA106771C2 (uk) 2014-10-10
EP3421493C0 (en) 2024-01-17
HN2012000708A (es) 2015-06-22
GEP201706604B (en) 2017-01-25
IL254004A0 (en) 2017-10-31
SG10201704933PA (en) 2017-07-28
US10385125B2 (en) 2019-08-20
US20200002413A1 (en) 2020-01-02
PT2488551T (pt) 2018-10-31
PL3421493T3 (pl) 2024-04-29
LT2488551T (lt) 2018-10-25
EP2488551B1 (en) 2018-07-25
US20110117086A1 (en) 2011-05-19
JP6272793B2 (ja) 2018-01-31
GT201200114A (es) 2014-08-11
SMT201800628T1 (it) 2019-01-11
CR20120184A (es) 2012-08-20
CL2012000914A1 (es) 2012-09-14
JP5985987B2 (ja) 2016-09-06
BR112012008818B1 (pt) 2021-10-19
EA029271B1 (ru) 2018-03-30
CA2777691A1 (en) 2011-04-21
NI201200054A (es) 2012-08-20
NZ599971A (en) 2014-12-24
US20220195035A1 (en) 2022-06-23
EP3421493A1 (en) 2019-01-02
IL254004B2 (en) 2023-06-01
MA33747B1 (fr) 2012-11-01
US10377821B2 (en) 2019-08-13
EA201791876A1 (ru) 2018-01-31
HK1178183A1 (zh) 2013-09-06
EA201200597A1 (ru) 2012-12-28
US10385124B2 (en) 2019-08-20
TWI537002B (zh) 2016-06-11
PL2488551T3 (pl) 2019-01-31
HRP20181645T1 (hr) 2018-12-14
WO2011045080A3 (en) 2011-07-07
PE20121649A1 (es) 2012-12-08
DK2488551T3 (en) 2018-10-08
KR101640520B1 (ko) 2016-07-19
EP3421493B1 (en) 2024-01-17
CU20120060A7 (es) 2013-04-19

Similar Documents

Publication Publication Date Title
ES2690943T3 (es) Anticuerpos monoclonales contra la progastrina y sus utilizaciones
ES2754774T3 (es) Profilaxis de cáncer colorrectal y gastrointestinal
AU2017202880B2 (en) Monoclonal Antibodies to Progastrin and their uses
HK40002657A (en) Monoclonal antibodies to progastrin and their uses
HK40002657B (en) Monoclonal antibodies to progastrin and their uses
EA041823B1 (ru) Моноклональные антитела к прогастрину и их применение
HK1178183B (en) Monoclonal antibodies to progastrin and their uses